(Updated) AMSTERDAM, THE NETHERLANDS — Another oral factor Xa inhibitor, this time the once-daily edoxaban (Lixiana, Daiichi-Sankyo), has shown it may be at least as effective as warfarin for ...
Please provide your email address to receive an email when new articles are posted on . Patients with RA taking tofacitinib 5 mg did not have elevated risk for cardiovascular events compared with ...
A new guideline for acute pulmonary embolism developed by 10 major specialty societies introduces a novel PE clinical ...
GERRARDS CROSS, England, NICE Final Appraisal Determination recommends that edoxaban is a cost effective use of NHS resources. The National Institute for Health and Care Excellence (NICE) has ...
European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE In the AMPLIFY trial, Eliquis was ...
ROME, Italy—In patients with suspected venous thromboembolism, use of a clinical algorithm that relies on a simplified scoring system for risk stratification and D-dimer testing can safely exclude ...
Leawood, KS - The American College of Physicians and American Academy of Family Physicians announced clinical practice guidelines for the diagnosis and management of venous thromboembolism (VTE), ...
This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators. Venous thromboembolism (VTE) among patients with lupus nephritis (LN) is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results